A Ph2 Randomized Trial to Evaluate the Safety Preliminary Efficacy and Biomarker Response of Host Directed Therapies Added to Rifabutin-modified Standard Therapy in Adults With Drug-Sensitive Smear-Positive Pulmonary TB
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Auranofin (Primary) ; Colecalciferol (Primary) ; Dovramilast (Primary) ; Everolimus (Primary) ; Rifabutin
- Indications Pulmonary tuberculosis
- Focus Adverse reactions
- Acronyms TBHDT
- 22 Jun 2020 According to an Amgen media release, the company is interested in partnering this program with a non-government organization (NGO) for further development.
- 09 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2020.